Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.
News|Articles|January 23, 2026
- Vol.27/No.2
- Volume 27
- Issue 2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
Author(s)Kyle Doherty
Fact checked by: Cheney Gazzam Baltz
Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.
Advertisement
Advertisement
In 2025, more than 60 agents and combinations, including biosimilars, earned accelerated, regular, or expanded approvals from the FDA, reshaping the treatment paradigms of multiple disease states and offering additional options for patients.
Related to this article
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
Aaron Gerds, MD, outlines how cytopenias affect patients with myelofibrosis and how these can help drive JAK inhibitor selection.
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.
Philip A. Philip, MD, discusses TTFields, the recent approval of this modality in pancreatic cancer, and phase 3 data in locally advanced disease.
Advertisement
Advertisement